Michael Chambers is the founding CEO of Aldevron, a company that specializes in nucleic acid, protein, and enzyme production and that has developed novel quality systems and technologies to accelerate the genetic medicine sector. The company was acquired by Danaher for $9.6 billion in 2021, and Chambers now advises Aldevron on opportunities including automating and miniaturizing biomanufacturing. He also leads an investment group seeking to make genomic medicines, AI, and other transformative technologies broadly accessible; and he serves on the boards of Sarepta Therapeutics, Lykan Biosciences, Agathos, Calviri, and the Centurion Foundation. A graduate of North Dakota State University — where he earned degrees in chemistry, microbiology, and biotechnology — Chambers founded Aldevron in 1998 and served as its chief executive officer and chairman for 21 years. He currently serves on the Institute’s Ad Hoc Committee.